Literature DB >> 6753886

Nifedipine in the treatment of hypertension: report of a double-blind controlled trial.

S Bayley, R J Dobbs, B F Robinson.   

Abstract

1 The effect of oral nifedipine has been examined in patients with hypertension in whom arterial pressure was not adequately controlled by the combination of a beta-adrenoceptor antagonist (or alpha-methyldopa) and a diuretic. 2 In 42 patients, nifedipine (10 mg capsules) was added to the existing therapy in a final dose of 20-60 mg daily. Six patients had to stop the drug on account of side-effects. In the 36 patients who continued treatment, arterial pressure fell by an average of 24/9 mmHg supine and 26/10 mmHg standing. 3 In 11 of these patients who subsequently completed a double-blind, cross-over, placebo controlled trial, nifedipine (30-60 mg daily) was found to reduce arterial pressure by an average of 19/11 mmHg supine and 21/12 mmHg standing. 4 In all 11 patients who were changed to a sustained release preparation of nifedipine, control of arterial pressure was at least as good as it had been when taking the capsules.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6753886      PMCID: PMC1427595          DOI: 10.1111/j.1365-2125.1982.tb02021.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  9 in total

1.  Relation of hydralazine plasma concentration to dosage and hypotensive action.

Authors:  R Zacest; J Koch-Weser
Journal:  Clin Pharmacol Ther       Date:  1972 May-Jun       Impact factor: 6.875

2.  Production of ischaemic cardiac pain by nifedipine.

Authors:  A G Jariwalla; E G Anderson
Journal:  Br Med J       Date:  1978-05-06

3.  Short- and long-term efficacy of a calcium-antagonistic agent (nifedipine) combined with methyldopa in the treatment of severe hypertension.

Authors:  M D Guazzi; C Fiorentini; M T Olivari; A Bartorelli; G Necchi; A Polese
Journal:  Circulation       Date:  1980-05       Impact factor: 29.690

4.  [Electromechanical uncoupling of vascular smooth muscle as the basic principle of coronary dilatation by 4-(2'-nitrophenyl-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylic acid dimethyl ester (BAY a 1040, Nifedipine). 1. The significance of Ca ++ ions for the bioelectrical and mechanical activity of smooth muscle].

Authors:  G Grün; A Fleckenstein
Journal:  Arzneimittelforschung       Date:  1972-02

5.  Nifedipine, a new antihypertensive with rapid action.

Authors:  M Guazzi; M T Olivari; A Polese; C Fiorentini; F Magrini; P Moruzzi
Journal:  Clin Pharmacol Ther       Date:  1977-11       Impact factor: 6.875

6.  Treatment of hypertension with nifedipine, a calcium antagonistic agent.

Authors:  M T Olivari; C Bartorelli; A Polese; C Fiorentini; P Moruzzi; M D Guazzi
Journal:  Circulation       Date:  1979-05       Impact factor: 29.690

7.  Response of forearm resistance vessels to verapamil and sodium nitroprusside in normotensive and hypertensive men: evidence for a functional abnormality of vascular smooth muscle in primary hypertension.

Authors:  B F Robinson; R J Dobbs; S Bayley
Journal:  Clin Sci (Lond)       Date:  1982-07       Impact factor: 6.124

8.  Effects of nifedipine on resistance vessels, arteries and veins in man.

Authors:  B F Robinson; R J Dobbs; C R Kelsey
Journal:  Br J Clin Pharmacol       Date:  1980-11       Impact factor: 4.335

9.  Calcium antagonists decrease adrenal and vascular responsiveness to angiotensin II in normal man.

Authors:  J A Millar; K McLean; J L Reid
Journal:  Clin Sci (Lond)       Date:  1981-12       Impact factor: 6.124

  9 in total
  17 in total

1.  Pharmacokinetics of nifedipine derived from a new retard tablet formulation.

Authors:  A Avgerinos; J W Gorrod
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1990 Oct-Dec       Impact factor: 2.441

Review 2.  Nifedipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in ischaemic heart disease, hypertension and related cardiovascular disorders.

Authors:  E M Sorkin; S P Clissold; R N Brogden
Journal:  Drugs       Date:  1985-09       Impact factor: 9.546

3.  Long-acting nifedipine versus metoprolol as monotherapy for essential hypertension. A randomized, controlled crossover study.

Authors:  K S Woo; C O Pun
Journal:  West J Med       Date:  1990-02

4.  Nifedipine as low-dose monotherapy for essential hypertension: a primary care study.

Authors:  L D Ritchie; L T Harrington; A R MacGregor; M J Vandenburg
Journal:  Cardiovasc Drugs Ther       Date:  1989-06       Impact factor: 3.727

Review 5.  The management of hypertension.

Authors:  B N Prichard; C W Owens
Journal:  Br J Clin Pharmacol       Date:  1986       Impact factor: 4.335

6.  Acute treatment of hypertensive crisis with nifedipine.

Authors:  F T Huysmans; H E Sluiter; T A Thien; R A Koene
Journal:  Br J Clin Pharmacol       Date:  1983-12       Impact factor: 4.335

7.  Dose response and length of action of nifedipine capsules and tablets in patients with essential hypertension: a randomised crossover study.

Authors:  F P Cappuccio; N D Markandu; F A Tucker; G A MacGregor
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

8.  Felodipine--a new vasodilator, in addition to beta-receptor blockade in hypertension.

Authors:  D Elmfeldt; T Hedner
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

9.  Comparison of nifedipine, prazosin and hydralazine added to treatment of hypertensive patients uncontrolled by thiazide diuretic plus beta-blocker.

Authors:  L E Ramsay; L Parnell; P C Waller
Journal:  Postgrad Med J       Date:  1987-02       Impact factor: 2.401

Review 10.  Treatment of severe hypertension and hypertensive crises with nifedipine.

Authors:  M C Houston
Journal:  West J Med       Date:  1987-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.